Ueda K, Kato H, Fujino T, Nanjo K, Noguchi H, Numa F, Narimatsu A, Nakamura Y, Torigoe T, Ito T
Gynecol Obstet Invest. 1987;24(1):62-7. doi: 10.1159/000298776.
The efficacy of bromocriptine therapy was studied in 84 normoprolactinemic infertile patients. Bromocriptine (2.5-5.0 mg/day) was given for at least 1 month. Bromocriptine therapy was effective in 54 of 84 cases (64%), including 6 of 15 (40%) cases with amenorrhea, 16 of 24 cases (67%) with anovulatory cycle, 9 of 15 cases (60%) with delayed ovulation and 23 of 30 cases (77%) with luteal phase defect. Sixteen cases were able to conceive with bromocriptine alone. Twenty-five patients who did not respond to bromocriptine were treated with a combination therapy consisting of bromocriptine and clomiphene. Of the 25 cases, 14 responded to the therapy, and 6 of them were able to conceive. The response of prolactin to domperidone (10 mg, i.v.) was significantly (p less than 0.01) higher in the group responding to bromocriptine than in the nonresponding group. These results indicate that the administration of bromocriptine is an effective therapy for patients with normoprolactinemic endocrine disorders, and that domperidone may be useful in selecting the candidates for bromocriptine therapy.
对84例催乳素水平正常的不孕患者进行了溴隐亭治疗疗效的研究。给予溴隐亭(2.5 - 5.0毫克/天)至少1个月。84例患者中有54例(64%)溴隐亭治疗有效,其中15例闭经患者中有6例(40%)有效,24例无排卵周期患者中有16例(67%)有效,15例排卵延迟患者中有9例(60%)有效,30例黄体期缺陷患者中有23例(77%)有效。16例患者单用溴隐亭即可受孕。25例对溴隐亭无反应的患者接受了溴隐亭与克罗米芬联合治疗。25例患者中,14例对该治疗有反应,其中6例受孕。在对溴隐亭有反应的组中,催乳素对多潘立酮(10毫克,静脉注射)的反应显著高于无反应组(p < 0.01)。这些结果表明,溴隐亭给药对催乳素水平正常的内分泌紊乱患者是一种有效的治疗方法,且多潘立酮可能有助于选择溴隐亭治疗的候选者。